Loring Wolcott & Coolidge Fiduciary Advisors’s Voyager Therapeutics VYGR Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,100	Closed	-$36K	–	721
2019 Q3	$36K	Hold	2,100	–	–	﹤0.01%	448
2019 Q2	$57K	Hold	2,100	–	–	﹤0.01%	392
2019 Q1	$40K	Hold	2,100	–	–	﹤0.01%	422
2018 Q4	$20K	Hold	2,100	–	–	﹤0.01%	524
2018 Q3	$40K	Hold	2,100	–	–	﹤0.01%	442
2018 Q2	$41K	Hold	2,100	–	–	﹤0.01%	449
2018 Q1	$39K	Hold	2,100	–	–	﹤0.01%	470
2017 Q4	$35K	Buy	+2,100	New	+$36K	﹤0.01%	472

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's VYGR Position: Q4 2019 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Voyager Therapeutics (VYGR) in Q4 2019, closing a stake of 2,100 shares — an estimated $36K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in VYGR in Q4 2017 and held it in 8 quarters. The position peaked at $57K in Q2 2019. 138 funds tracked by Wall St. Rank hold VYGR as of Q4 2019.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Voyager Therapeutics position as of Q4 2019 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 2,100 Voyager Therapeutics shares in Q4 2019, an estimated $36K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Voyager Therapeutics in Q4 2017 and held it in 8 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Voyager Therapeutics position peaked at $57K in Q2 2019.
138 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2019.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2019, filed 22 Jan 2020.